Black and Latino people use 10% to 40% fewer prescription drugs because of high costs, according to a report by Patients for Affordable Drugs.
2 months ago

Vishal Manchanda, pharma analyst at Systematix Group and Aditya Khemka, fund manager at InCred Healthcare PMS discuss the impact of the...
8 months ago

Natco Pharma share price gained more than 7% to scale 52 week highs on Thursday during the intraday trades. The robust US sales growth led by Revlimid generics...
3 months ago

Celgene Corp. has thwarted rival drugmakers eager to make cheaper versions of medicines for a form of blood cancer.
78 months ago

Recent legislation would require drug companies to pay rebates to the federal government when annual increases in prescription drug prices...
33 months ago

While Dr Reddy's recorded its highest-ever quarterly revenue in Q3, most of the growth was fueled by a higher-than-expected contribution...
10 months ago

Rep. Katie Porter of California grilled Celgene CEO Mark Alles on Wednesday over price hikes on a cancer drug that she said resulted in a bonus of half a...
50 months ago

Health systems say deals between Revlimid's owners, Celgene and Bristol-Myers Squibb, and other pharmas are anticompetitive and drive higher...
13 months ago

Celgene hiked the list prices of key cancer meds Revlimid and Pomalyst by 9% this month, taking their cumulative increases for the year to nearly double the...
85 months ago

Bristol Myers Squibb reported a higher-than-expected third-quarter profit on Thursday, citing strong sales of established drugs like blood...
1 month ago